Holen Sie sich die Stockscreener-App
6.51
1.72%
0.11
Handel nachbörslich:
6.51
Schlusskurs vom Vortag:
$6.40
Offen:
$6.38
24-Stunden-Volumen:
1.64M
Relative Volume:
1.19
Marktkapitalisierung:
$421.10M
Einnahmen:
$202.09M
Nettoeinkommen (Verlust:
$-61.69M
KGV:
-6.0278
EPS:
-1.08
Netto-Cashflow:
$-35.64M
1W Leistung:
+2.20%
1M Leistung:
-31.33%
6M Leistung:
-56.72%
1J Leistung:
-51.92%
1-Tages-Spanne:
$6.29
$6.74
1-Wochen-Bereich:
$5.71
$6.74
52-Wochen-Spanne:
$5.71
$17.82
Evolus Inc Stock (EOLS) Company Profile
Firmenname
Evolus Inc
Sektor
Telefon
(949) 284-4555
Adresse
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Vergleichen Sie EOLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
6.51 | 413.99M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.96B | 957.25M | 5.31B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.26B | 1.98B | 0 | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Herabstufung | Needham | Buy → Hold |
| 2025-04-17 | Eingeleitet | BTIG Research | Buy |
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-06-23 | Eingeleitet | Needham | Buy |
| 2022-05-12 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-04-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-24 | Herabstufung | Truist | Buy → Hold |
| 2020-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-02-06 | Fortgesetzt | Mizuho | Buy |
| 2019-11-26 | Eingeleitet | SVB Leerink | Outperform |
| 2019-09-05 | Fortgesetzt | Mizuho | Buy |
| 2019-06-28 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-29 | Eingeleitet | Stifel | Buy |
Alle ansehen
Evolus Inc Aktie (EOLS) Neueste Nachrichten
Evolus Q2 2025: Unpacking Contradictions in Toxin Demand, Evolysse Launch, and Consumer Sentiment - AInvest
How liquid is Evolus Inc. stockNext Day Profit Stock Signals - newsyoung.net
Evolus plunges after Q2 miss, guidance cut; Needham downgrades - MSN
Analysts Just Slashed Their Evolus, Inc. (NASDAQ:EOLS) EPS Numbers - simplywall.st
Evolus (EOLS): Navigating Earnings Revisions and Long-Term Potential in the Aesthetic Medicine Sector - AInvest
Evolus, Inc. Sees Significant Downgrades to Consensus EPS Estimates - AInvest
The recent earnings and revenue miss by Evolus EOLS -2.80% (EOLS) has sent shockwaves through the aesthetic medicine sector, with sharp downward revisions in analyst expectations raising questions about the company's long-term viability. Q2 2025 res - AInvest
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
When Will Evolus, Inc. (NASDAQ:EOLS) Turn A Profit? - 富途牛牛
Evolus, Inc. Faces Financial Uncertainty Due to Consumer Spending Risks and Economic Volatility - AInvest
Evolus Receives Buy Rating from Leerink Partners - AInvest
Evolus, Inc. Advances Safety Study of NUCEIVA for Glabellar Lines - TipRanks
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $18 to $20 - 富途牛牛
Evolus, Inc. (NASDAQ:EOLS) Q2 2025 Earnings Call Transcript - Insider Monkey
Evolus, Inc. Faces Financial Instability Amid Economic Uncertainty and Consumer Spending Risks - TipRanks
Evolus Q2 Earnings: Mixed Sentiments and Strategic Goals for Growth - AInvest
Evolus Maintains Buy Rating Amid Market Challenges Despite Reset in 2025 Revenue Guidance - AInvest
Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates - MSN
Evolus, Inc. Earnings Call: Mixed Sentiments and Strategic Goals - TipRanks
Evolus Appoints New Principal Financial Officer - MSN
Evolus 2025 Q2 Earnings Misses Targets, Net Loss Widens by 51% - AInvest
Evolus stock down on Q2 miss; Needham downgrades (EOLS:NASDAQ) - Seeking Alpha
Evolus, Inc. shares fall 30.53% intraday after disappointing Q2 earnings and lowered 2025 sales target. - AInvest
Evolus Sees Steady Gains And Eyes Profit Next Year - Finimize
Evolus Reports Q2 Revenue of $69.4mln, Misses Estimates by 15.4%, Lowers Full-Year Guidance - AInvest
Evolus stock price target lowered to $20 by H.C. Wainwright on market headwinds - Investing.com Canada
Evolus price target lowered to $18 from $21 at BTIG - TipRanks
Evolus: HC Wainwright Maintains Buy, PT Down to $20 from $27 - AInvest
Evolus stock price target lowered to $18 at BTIG on Q2 revenue miss By Investing.com - Investing.com South Africa
Evolus stock price target lowered to $18 at BTIG on Q2 revenue miss - Investing.com India
Evolus Stock Plunges 25.14% on Disappointing Earnings - AInvest
Evolus Q2 2025 slides: Filler launch drives market expansion despite earnings miss - Investing.com Nigeria
Evolus, Inc. Reports Q2 2025 Financial Results - TipRanks
Evolus outlines $700M 2028 revenue target and cost realignment amid market softness - MSN
Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Evolus, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:EOLS) - Seeking Alpha
Earnings call transcript: Evolus Q2 2025 misses EPS and revenue forecasts - Investing.com Nigeria
Evolus, Inc. SEC 10-Q Report - TradingView
Evolus earnings missed by $0.17, revenue fell short of estimates - Investing.com Australia
Evolus reports Q2 EPS (27c), consensus (9c) - TipRanks
RENEW 8-K: Ninth SPAC Extension Adds $250k to Trust, Deadline Sep 5 2025 | EOLS SEC FilingForm 8-K - Stock Titan
Evolus, Inc. Advances NUCEIVA Safety Study: Key Insights for Investors - TipRanks
Is it the right time to buy Evolus Inc. stockGet expert advice on portfolio optimization - Jammu Links News
What institutional investors are buying Evolus Inc. stockMaximize returns with timely market signals - Jammu Links News
What drives Evolus Inc. stock priceUnlock exclusive stock analysis for investors - Jammu Links News
Is Evolus Inc. a good long term investmentUnlock powerful market trend analysis - Jammu Links News
What are Evolus Inc. company’s key revenue driversGrow your portfolio with growth-oriented stocks - Jammu Links News
How strong is Evolus Inc. company’s balance sheetBreakout stock performance - Jammu Links News
How many analysts rate Evolus Inc. as a “Buy”Capitalize on momentum-driven opportunities - Jammu Links News
What is the dividend policy of Evolus Inc. stockTrack top-performing stocks effortlessly - Jammu Links News
Should I hold or sell Evolus Inc. stock in 2025Exceptional financial outcomes - Jammu Links News
Finanzdaten der Evolus Inc-Aktie (EOLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):